Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial

International Journal of Reproductive BioMedicine

Volumn 11, Issue 8, 2013, Pages 611-618

  Amooee, Sedigheh ^a   Parsanezhad, Mohammad Ebrahim ^a   Shirazi, Maryam Ravanbod ^a   Alborzi, Saeed ^a   Samsami, Alamtaj ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chromium picolinate; Clomiphen resistant; Metformin; Polycystic ovary syndrome (PCOS)

Indexed keywords

EID: 84926350773     PISSN: 24764108     EISSN: 24763772     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Parsanezhad ME, Alborzi S, Zarei A, Dehbashi S, Omrani G. Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin. Int J Gynaecol Obstet 2001; 75: 43-50.
2. Whitaker KN. Polycystic ovary syndrome: an overview. J Pharm Pract 2011; 24: 94-101.
3. Lucidi RS, Thyer AC, Easton AC, Holden AC, Schenken RS, Brzyski RG. Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril 2005; 84: 1755-1757.
4. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health 2011; 3: 25-35.
5. Lydic ML, McNurlan M, Bembo S, Mitchell L, Komaroff E, Gelato M. Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome. Fertil Steril 2006; 86: 243-246.
6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term healthy risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
7. Azziz R, Dewailly D, Owerbach D. Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 1994; 78: 810-815.
8. White PC, Curnow KM, Pascoe L. Disorders of steroid 11β-hydroxylase isozymes. Endocr Rev 1994; 15: 421-438.
9. Stearns DM. Is chromium a trace essential metal? Biofactors 2000; 11: 149-162.
10. Hummel M, Standl E, Schnell O. Chromium in metabolic and cardiovascular disease. Horm Metab Res. 2007; 39: 743-51.
11. Wang ZQ, Cefalu WT. Current concepts about chromium supplementation intype2 diabetes and insulin resistance. Curr Diab Rep 2010; 10: 145-151.
12. Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol 2003; 17: 51-56.
13. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004; 81: 114-119.
14. Aruna J, Mittal S, Kumar S, Misra R, Dadhwal V, Vimala N. Metformin therapy in women with polycystic ovary syndrome. Int J Gynecol Obstet 2004; 87: 237-241.
15. Anderson RA. Effects of chromium on body composition and weight loss. Nutr Rev 1998; 56: 266-270.
16. Albarracin CA, Fuqua BC, Evans JL, Goldfine ID. Goldfine Chromium picolinate and biotin combination improves glucose metabolism in treated uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev 2008; 24: 41-51.
17. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenisim and hyper insulinemia in women with polycystic ovary syndrome Fertil Steril 2000; 73: 1149-1154.